ESLA - Estrella Immunopharma, Inc. Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

ESLA

ESTRELLA IMMUNOPHARMA, INC.

NASDAQ

$0.53

▲ UP 0.57% (0.00)

KEY STATISTICS

Market Cap$22.57 M

52w High$3.15

52w Low$0.51

Dividend Yield—

Frequency—

P/E-2.15

Volume54.19K

Shares Out.42.67M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Cheng Liu

ABOUT

SECTOR

Healthcare

WENT PUBLIC

September 14, 2021

METHOD OF GOING PUBLIC

N/A

FULL TIME EMPLOYEES

UPCOMING EARNINGS

DateDec 2, 2026

DayWednesday

Rev. Est.—

DEC

WED

PRICE

$0.53 ▲ UP 0.57% (+$0.00)

About Estrella Immunopharma, Inc.

https://www.estrellabio.com ↗

Estrella Immunopharma, Inc. is a preclinical biopharmaceutical company in California developing T-cell therapies for blood cancers and solid tumors, with lead candidates EB103 and EB104, and a partnership with Imugene Limited.

INDUSTRY

Biotechnology

A PRODUCT ESTRELLA IMMUNOPHARMA, INC. IS KNOWN FOR

EB103

EB103 is a CD19-targeted ARTEMIS® T-cell therapy by Estrella Immunopharma, currently in Phase I/II trials for B-cell Non-Hodgkin Lymphoma, showing a 100% Complete Response in high-dose patients.